Re: Metotrexát a Crohnova nemoc

SUMMARY:

Methotrexate is a folic acid antagonist used in the treatment of a wide range of neoplastic conditions including leukaemias, Non-Hodgkin’s lymphoma, soft tissue sarcomas, osteogenic sarcomas and solid tumours. Methotrexate is also used in the treatment of rheumatoid arthritis and severe psoriasis.
There is very little published information on the potential teratogenicity following paternal exposure to methotrexate. There have been reports of alterations of the spermatozoa and oligospermia following exposure to methotrexate, however these effects appear to be reversible on cessation of treatment.
In practice, it is advisable to wait about six months (two sperm cycles) after such exposures before conception is planned. It is unusual for an increased risk of congenital malformations to be associated with exposure to drugs and/or chemicals in the father alone, unless they cause chromosomal abnormalities/point mutations.
A pregnancy following paternal exposure to methotrexate would not be regarded as an indication for termination of pregnancy or any invasive diagnostic procedures.